Aigen Investment Management LP Reduces Holdings in Repligen Co. (NASDAQ:RGEN)

Aigen Investment Management LP lowered its stake in shares of Repligen Co. (NASDAQ:RGEN) by 55.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 3,275 shares of the biotechnology company’s stock after selling 4,106 shares during the quarter. Aigen Investment Management LP’s holdings in Repligen were worth $487,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Andra AP fonden purchased a new position in shares of Repligen during the 2nd quarter worth approximately $25,000. Lazard Asset Management LLC grew its stake in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares during the period. UMB Bank n.a. raised its holdings in Repligen by 138.3% in the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares in the last quarter. Blue Trust Inc. lifted its position in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 127 shares during the period. Finally, International Assets Investment Management LLC bought a new stake in shares of Repligen during the 2nd quarter valued at $33,000. 97.64% of the stock is owned by institutional investors.

Repligen Stock Down 5.3 %

RGEN stock opened at $142.43 on Friday. The stock has a market capitalization of $7.98 billion, a P/E ratio of -384.94, a P/E/G ratio of 4.27 and a beta of 0.96. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The business has a fifty day moving average price of $141.59 and a 200-day moving average price of $144.78.

Repligen (NASDAQ:RGEN) last posted its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million for the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter in the prior year, the business earned $0.23 EPS. The business’s revenue for the quarter was up 9.7% compared to the same quarter last year. Equities analysts forecast that Repligen Co. will post 1.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

RGEN has been the subject of several research reports. Wells Fargo & Company began coverage on shares of Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Stephens reiterated an “overweight” rating and set a $170.00 target price on shares of Repligen in a report on Tuesday, July 30th. Wolfe Research began coverage on Repligen in a research note on Thursday. They issued a “peer perform” rating on the stock. StockNews.com upgraded Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $205.00 target price on shares of Repligen in a report on Thursday, September 26th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, Repligen presently has an average rating of “Moderate Buy” and an average target price of $190.25.

Insider Buying and Selling

In other news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.